Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with/without metabolic syndrome

Journal of Clinical Laboratory Analysis

Volumn 25, Issue 4, 2011, Pages 289-295

  Usta, Murat ^a   Turan, Enver ^b   Aral, Hale ^c   Inal, Berrin Bercik ^c   Gurel, Mehmet Salih ^c   Guvenen, Guvenc ^c  

^a Ministry of Health Sivas Numune Hospital   (Turkey)

^b Ministry of Health Batman Regional Government Hospital   (Turkey)

^c ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Metabolic syndrome; Oxidative stress; Paraoxonase 1; Psoriasis

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ANALYTICAL PARAMETERS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OXIDATION; PSORIASIS; PSORIASIS EN PLAQUE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TOTAL ANTIOXIDANT CAPACITY; TOTAL OXIDANT STATUS; WAIST CIRCUMFERENCE;

ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATIVE STRESS; PSORIASIS;

EID: 79960678246     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20471     Document Type: Article

References (36)

1. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: Epidemiology and pathophysiology. Curr Opin Rheumatol 2008;20:416-422.
2. Späh F. Inflammation in atherosclerosis and psoriasis: Common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008;159:10-17.
3. Portugal M, Barak V, Ginsburg I, Kohen R. Interplay among oxidants, antioxidants, and cytokines in skin disorders: Present status and future considerations. Biomed Pharmacother 2007;61:412-422.
4. Briganti S, Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What's new. J Eur Acad Dermatol Venereol 2003;17:663-669.
5. Report of a WHO Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1 Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, Department of Noncommunicable Disease Surveillance, 1999.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-2497.
7. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Concensus Group. The metabolic syndrome-A new worldwide definition. Lancet 2005;366:1059-1062.
8. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol 2007;157:68-73.
9. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-328.
10. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Dermatol Venereol 2007;87:506-509.
11. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008;216:152-155.
12. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case-control study. J Am Acad Dermatol 2007;56:629-634.
13. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: A population-based study. Br J Dermatol 2008;159:1331-1337.
14. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76.
15. Ferré N, Camps J, Fernández-Ballart J, et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 2003;49:1491-1497.
16. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-135.
17. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN. Presence of paraoxonase in human interstitial fluid. FEBS Lett 1997;416:377-380.
18. Canales A, Sánchez-Muniz FJ. Paraoxonase, something more than an enzyme? Med Clin (Barc) 2003;121:537-548.
19. Josse D, Xie W, Renault F, et al. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry 1999;38:2816-2825.
20. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000;49:1400-1405.
21. Garin MC, Kalix B, Morabia A, James RW. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 2005;90:2264-2269.
22. Sentí M, Tomás M, Fitó M, et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003; 88:5422-5426.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
24. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol 2004;51:563-569.
25. Freidewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-119.
27. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-1111.
28. Toker A, Kadi M, Yildirim AK, Aksoy H, Akçay F. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 2009;27:176-180.
29. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004;89:4963-4971.
30. Buckingham BA, Sandborg CI. A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus. Clin Immunol 2000;96:86-90.
31. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006;298:309-319.
32. Lange RW, Germolec DR, Foley JF, Luster MI. Antioxidants attenuate anthralin-induced skin inflammation in BALB/c mice: Role of specific proinflammatory cytokines. J Leukoc Biol 1998;64:170-176.
33. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-230.
34. Yildirim M, Inaloz HS, Baysal V, Delibas N. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003;17:34-36.
35. Severin E, Nave B, Ständer M, Ott R, Traupe H. Total antioxidative capacity is normal in sera from psoriasis patients despite elevated bilirubin, tocopherol and urate levels. Dermatology 1999;198:336-339.
36. Vanizor KB, Orem A, Cimşit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003;328:71-82.